vs
CytomX Therapeutics, Inc.（CTMX）与Dominari Holdings Inc.（DOMH）财务数据对比。点击上方公司名可切换其他公司
Dominari Holdings Inc.的季度营收约是CytomX Therapeutics, Inc.的1.6倍（$30.1M vs $18.7M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -438.1%，领先437.3%），Dominari Holdings Inc.同比增速更快（220.4% vs -25.7%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
CTMX vs DOMH — 直观对比
营收规模更大
DOMH
是对方的1.6倍
$18.7M
营收增速更快
DOMH
高出246.1%
-25.7%
净利率更高
CTMX
高出437.3%
-438.1%
两年增速更快
DOMH
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $30.1M |
| 净利润 | $-154.0K | $-131.8M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | -8.9% |
| 净利率 | -0.8% | -438.1% |
| 营收同比 | -25.7% | 220.4% |
| 净利润同比 | 97.6% | -12426.2% |
| 每股收益（稀释后） | — | $-6.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXDOMH
| Q4 25 | — | $30.1M | ||
| Q3 25 | — | $50.8M | ||
| Q2 25 | $18.7M | $34.1M | ||
| Q1 25 | $50.9M | $8.1M | ||
| Q4 24 | $38.1M | $9.4M | ||
| Q3 24 | $33.4M | $4.0M | ||
| Q2 24 | $25.1M | $6.2M | ||
| Q1 24 | $41.5M | $1.4M |
净利润CTMXDOMH
| Q4 25 | — | $-131.8M | ||
| Q3 25 | — | $125.2M | ||
| Q2 25 | $-154.0K | $16.6M | ||
| Q1 25 | $23.5M | $-32.5M | ||
| Q4 24 | $18.9M | $1.1M | ||
| Q3 24 | $5.7M | $-4.2M | ||
| Q2 24 | $-6.5M | $-6.1M | ||
| Q1 24 | $13.8M | $-5.4M |
营业利润率CTMXDOMH
| Q4 25 | — | -8.9% | ||
| Q3 25 | — | -3.1% | ||
| Q2 25 | -6.9% | -57.0% | ||
| Q1 25 | 44.4% | -394.6% | ||
| Q4 24 | 46.4% | 0.4% | ||
| Q3 24 | 12.3% | -79.1% | ||
| Q2 24 | -33.7% | -44.3% | ||
| Q1 24 | 28.1% | -205.2% |
净利率CTMXDOMH
| Q4 25 | — | -438.1% | ||
| Q3 25 | — | 246.4% | ||
| Q2 25 | -0.8% | 48.7% | ||
| Q1 25 | 46.2% | -400.5% | ||
| Q4 24 | 49.6% | 11.4% | ||
| Q3 24 | 17.2% | -104.2% | ||
| Q2 24 | -26.0% | -99.1% | ||
| Q1 24 | 33.3% | -398.0% |
每股收益（稀释后）CTMXDOMH
| Q4 25 | — | $-6.94 | ||
| Q3 25 | — | $7.27 | ||
| Q2 25 | — | $1.12 | ||
| Q1 25 | — | $-3.02 | ||
| Q4 24 | — | $0.21 | ||
| Q3 24 | — | $-0.67 | ||
| Q2 24 | — | $-1.01 | ||
| Q1 24 | — | $-0.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $80.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $69.4M |
| 总资产 | $175.1M | $112.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXDOMH
| Q4 25 | — | $80.5M | ||
| Q3 25 | — | $176.2M | ||
| Q2 25 | $49.0M | $28.2M | ||
| Q1 25 | $47.6M | $18.9M | ||
| Q4 24 | $38.1M | $8.2M | ||
| Q3 24 | $40.6M | $7.2M | ||
| Q2 24 | $43.2M | $12.1M | ||
| Q1 24 | $36.2M | $7.1M |
股东权益CTMXDOMH
| Q4 25 | — | $69.4M | ||
| Q3 25 | — | $210.2M | ||
| Q2 25 | $119.9M | $88.6M | ||
| Q1 25 | $25.0M | $42.4M | ||
| Q4 24 | $-456.0K | $39.9M | ||
| Q3 24 | $-23.5M | $38.3M | ||
| Q2 24 | $-31.2M | $42.4M | ||
| Q1 24 | $-31.7M | $47.7M |
总资产CTMXDOMH
| Q4 25 | — | $112.9M | ||
| Q3 25 | — | $223.4M | ||
| Q2 25 | $175.1M | $109.3M | ||
| Q1 25 | $98.5M | $52.3M | ||
| Q4 24 | $120.5M | $47.1M | ||
| Q3 24 | $139.0M | $43.4M | ||
| Q2 24 | $159.2M | $49.1M | ||
| Q1 24 | $184.7M | $52.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $22.7M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXDOMH
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $-4.9M | ||
| Q2 25 | $-15.8M | $-353.0K | ||
| Q1 25 | $-21.0M | $1.2M | ||
| Q4 24 | $-19.9M | $-16.7M | ||
| Q3 24 | $-20.7M | $-4.7M | ||
| Q2 24 | $-19.5M | $1.4M | ||
| Q1 24 | $-26.0M | $-8.6M |
自由现金流CTMXDOMH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
自由现金流率CTMXDOMH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
资本支出强度CTMXDOMH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CTMXDOMH
| Q4 25 | — | — | ||
| Q3 25 | — | -0.04× | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | -15.65× | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
